The Society for Immunotherapy of Cancer Consensus Statement on Immunotherapy for the Treatment of Squamous Cell Carcinoma of the Head and Neck (HNSCC)

This is a clinical practice guideline for adults with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC). The guideline examines the use of immunotherapy for the treatment of these patients, while specifically addressing the use of the anti programmed cell death protein (PD-1) monoclonal antibodies, nivolumab and pembrolizumab. Primary outcomes of interest are overall survival and quality of life.